Showing 4781-4790 of 7245 results for "".
- Study Links Structural and Immune Risk Factors to Skin Conditions in PWHhttps://practicaldermatology.com/news/study-links-structural-and-immune-risk-factors-to-skin-conditions-in-pwh/2483949/Nearly half of people living with HIV (PWH) are diagnosed with at least one dermatologic condition despite advances in antiretroviral therapy (ART), according to a longitudinal cohort study published through the DC Cohort. Accor
- Pfizer and GWU Renew Grant Program to Expand Teledermatology Access for Inflammatory Skin Conditionshttps://practicaldermatology.com/news/pfizer-and-gwu-renew-grant-program-to-expand-teledermatology-access-for-inflammatory-skin-conditions/2483889/Pfizer Global Medical Grants and The George Washington University (GWU) have renewed their joint grant program focused on broadening access to dermatologic care in underserved U.S. communities. According to a GWU press announc
- Dr. Karan Lal Shares 'Recipe' for Prescribing GLP-1shttps://practicaldermatology.com/news/dr-karan-lal-shares-recipe-for-prescribing-glp-1s/2483869/The increasingly understood relevance of weight-loss drugs to inflammatory skin conditions was a hot topic at the Skin of Color Update in New York, New York, and Karan Lal, DO, FAAD, shared his “recipe” for addressing it with patients. Dr. Lal first checks for prior diagnoses of diabetes m
- Dr. Jennifer Soung: Ask Patient’s Permission Before Talking GLP-1shttps://practicaldermatology.com/news/dr-jennifer-soung-ask-patients-permission-before-talking-glp-1s/2483863/GLP-1 treatments have become commonplace in dermatology practices, with both aesthetic and medical dermatology implications heavily involved. Talking to patients about the latter issue, however, can prove challenging. Despite the mounting literature indicating that GLP-1 agonists can help allevia
- Roflumilast 0.05% Gains FDA Approval for Children 2-5 with ADhttps://practicaldermatology.com/news/roflumilast-005-gains-fda-approval-for-children-2-5-with-ad/2483862/The US Food and Drug Administration (FDA) has approved roflumilast cream 0.05% (Zoryve®, Arcutis Biotherapeutics) for the treatment of mild-to-moderate atopic dermatitis (AD) in children 2 to 5 years old. This once-daily topical phosphodiesterase-4 (PDE4) inhibitor
- Latino Melanoma Patients Face Barriers to Early Diagnosis and Treatmenthttps://practicaldermatology.com/news/latino-melanoma-patients-face-barriers-to-early-diagnosis-and-treatment/2483846/A new qualitative study published in JAMA Dermatology explored persistent disparities Latino patients face in timely melanoma diagnosis and treatment, despite advances in therapy that have improved survival among non-Hispani
- FDA Approves Guselkumab for Children 6 and Older With PsOhttps://practicaldermatology.com/news/fda-approves-guselkumab-for-children-6-and-older-with-pso/2483604/The US Food and Drug Administration (FDA) has approved guselkumab (Tremfya®, Johnson & Johnson) for the treatment of children 6 and older, weighing at least 40 kg, with moderate-to-severe plaque psoriasis (PsO) or active psoriatic arthritis (PsA), making it the
- LEO Pharma Finalizes Acquisition of Spevigo® for Rare Dermatologic Diseaseshttps://practicaldermatology.com/news/leo-pharma-finalizes-acquisition-of-spevigo-for-rare-dermatologic-diseases/2483600/LEO Pharma has officially completed its acquisition of Spevigo® (spesolimab) from Boehringer Ingelheim, according to a press release from the manufacturer. The purchase represents the c
- Accelerated Phenotypic Aging Linked to Increased Mortality With PsOhttps://practicaldermatology.com/news/accelerated-phenotypic-aging-linked-to-increased-mortality-with-pso/2483591/A new analysis of US adult data has found that phenotypic age acceleration (PhenoAge-accel) is associated with increased risk of psoriasis and—when coexisting with the disease—elevated risk of all-cause and cardiovascular disease (CVD) mortality. The study, publishe
- FDA Approves Remibrutinib for Adults With CSUhttps://practicaldermatology.com/news/fda-approves-remibrutinib-for-adults-with-csu/2483590/The US Food and Drug Administration (FDA) has approved remibrutinib (Rhapsido, Novartis) as the first oral Bruton’s tyrosine kinase (BTK) inhibitor for the treatment of chronic spontaneous urticaria (CSU) in adults whose symptoms persist despite H1 antihistamine the